Metagenomic Next-Generation Sequencing in the Diagnosis of HHV-1 Reactivation in a Critically Ill COVID-19 Patient: A Case Report

Lei Shi, Han Xia, Matthew D. Moore, Chao Deng, Na Li, Hui Ren, Yunru Chen, Jinfeng Liu, Fenjing Du, Gezhi Zheng, Jing Li, Quying Han, Wanhua Fan, Feng Ye, Shumei Lin, Zhengwen Liu, Hongjuan Liu, Yawen Wang, Jian Yang, Qingguang Liu, Yingren Zhao and Tianyan Chen

Background: Secondary infections pose tremendous challenges in Coronavirus disease 2019 (COVID-19) treatment and are associated with higher mortality rates. Clinicians face the challenge of diagnosing viral infections because of low sensitivity of available laboratory tests.

Case Presentation: A 66-year-old woman initially manifested fever and shortness of breath. She was diagnosed as critically ill with COVID-19 using quantitative reverse transcription PCR (RT-qPCR) and treated with antiviral therapy, ventilator and extracorporeal membrane oxygenation (ECMO). However, after the condition was relatively stable for a few days, the patient deteriorated with fever, frequent cough, increased airway secretions, and increased exudative lesions in the lower right lung on chest X-rays, showing the possibility of a newly acquired infection, though sputum bacterial and fungal cultures and smears showed negative results. Using metagenomic next-generation sequencing (mNGS), we identified a reactivation of latent human herpes virus type 1 (HHV-1) in the respiratory tract, blood and gastrointestinal tract, resulting in a worsened clinical course in a critically ill COVID-19 patient on ECMO. Anti-HHV-1 therapy guided by these sequencing results effectively decreased HHV-1 levels, and improved the patient's clinical condition. After 49 days on ECMO and 67 days on the ventilator, the 66-year-old patient recovered and was discharged.

Conclusions: This case report demonstrates the potential value of mNGS for evidence-based treatment, and suggests that potential reactivation of latent viruses should be considered in critically ill COVID-19 patients.

Keywords: COVID-19, HHV-1, metagenomic next-generation sequencing (mNGS), diagnosis, case report
BACKGROUND

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the seventh known coronavirus that can infect humans after HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, and MERS-CoV. The Coronavirus disease 2019 (COVID-19) global pandemic caused by SARS-CoV-2 has affected 205,372,963 of the world’s population, with 4,334,178 total deaths, as of August 13, 2021 (https://coronavirus.jhu.edu/map.html). The symptoms in the majority of patients infected with SARS-CoV-2 have been relatively mild, but 10–15% patients developed severe infections (1). Compared with patients with mild symptoms, the severe patients are older, with more comorbidities and lower lymphocyte counts (2, 3) and experience higher mortality. Secondary infections or co-infections, mainly by bacteria or viruses, occur in 10–30% of hospitalized COVID-19 patients (4), contributing to the high incidence of severe infection and mortality of COVID-19.

Human herpes virus type 1 (HHV-1) is a double stranded DNA virus that infects a large population worldwide. According to the conservative estimate, more than 90% of the human adult population has latently infected by HHV-1 globally (5–8). HHV-1 establishes latent infection within ganglionic cells, of which the trigeminal ganglia are the most commonly affected. When the body’s immunity weakens, HHV-1 can be reactivated and cause opportunistic infection. The mortality of influenza patients is increased with concomitant HHV-1 infection, but the pathogenesis remains unclear (9). Whether SARS-CoV-2 coinfected HSV may aggravate the condition of COVID-19 has not been reported yet. We present a case of COVID-19 infection, followed by HHV-1 reactivation that exacerbated the condition of COVID-19.

CASE PRESENTATION

A 66-year-old woman presented to the First Affiliated Hospital of Xi’an Jiaotong University on February 5, 2020, with a 4-day history of fever and shortness of breath. Apart from hypertension, the patient had no other underlying medical conditions. Laboratory tests were unremarkable for a low lymphocyte count of $0.72 \times 10^9$ cells/L (reference range $1.1–3.2 \times 10^9$ cells/L) and high C-reactive protein of $71$ mg/L (reference range $0-10$ mg/L). The respiratory rate was $30$ breaths/min, and oxygen saturation was $83\%$ on ambient air. Chest computed tomography (CT) showed multifocal bilateral ground glass opacities (GGO) with patchy consolidations, prominent in the peripheral distribution on day 4 after symptom onset (Figure 1). Given a history of having contact with a confirmed COVID-19 patient and characteristic changes on CT imaging, a nasopharyngeal swab (NP) specimen was sent for SARS-CoV-2 testing by quantitative reverse transcription PCR (RT-qPCR). The swab was registered as positive for SARS-CoV-2 while antigen tests for influenza A and B registered negative.

Upon admission, arbidol for antiviral therapy (0.2 g, oral, three times daily) and moxifloxacin for anti-bacterial therapy (400 mg, intravenous drips, once a day) were implemented to control patient’s rapidly deteriorating condition. On Day 2 of hospitalization, the patient developed shortness of breath and chest tightness, and required supplemental oxygen via an oxymask (oxygen flow at 10 L/min). Vitals included: respiratory rate 30–45 breaths per minute, oxygen saturation of 93–97% via pulse oximetry, and arterial blood gas PO$_2$ $55$ mmHg on mask oxygen at 10 L/min. Non-invasive ventilator-assisted ventilation was initiated.

On Day 3, the patient’s chest tightness and shortness of breath persisted. Chest X-rays indicated a superimposed pneumonic process. Hypoxemia showed no significant improvement after increasing PEEP and oxygen concentration. Based on the Extracorporeal Life Support Organization guidelines, extracorporeal membrane oxygenation (ECMO) (V-V mode) was initiated on Day 5. During this period, the patient’s vital signs remained stable and SARS-CoV-2 viral copy number in NP samples continued to decrease (Figure 2).

On Day 14, the patient developed a frequent productive cough, and pulse oxygen saturation dropped to 88%, accompanied by increased heart rate (117 beats per minute), breathing rate (42 breaths per minute), and a temperature of 37.8°C. A small amount of light blood fluid was suctioned out of the endotracheal tube. Chest X-rays showed increased exudative lesions in the lower right lung. The white blood cell count increased to $18.39 \times 10^9$ cells/L (reference range $3.5–9.5 \times 10^9$ cells/L). Blood procalcitonin was negative, and sputum bacterial and fungal cultures and smears were negative, raising the possibility of a newly acquired infection, but with unknown etiology.

Abbreviations: COVID-19, Coronavirus disease 2019; HHV-1, Human herpes virus type 1; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; CT, Computed tomography; NP, nasopharyngeal swab; RT-qPCR, Quantitative reverse transcription PCR; ECMO, Extracorporeal membrane oxygenation; mNGS, Metagenomic next-generation sequencing.

FIGURE 1 | Representative images of the thoracic CT scans. Chest computed tomograms showing multifocal bilateral ground glass opacities with patchy consolidations, prominent in the peripheral distribution on day 4 after symptom onset.
To further identify the presence of any newly acquired respiratory pathogens, PACEseq metagenomic next-generation sequencing (mNGS) (Hugobiotech, Beijing) of sputum was performed on Day 16 for pan-pathogen detection. The mNGS report came out on Day 18 (48 h after inspection) and showed that in addition to SARS-CoV-2 (9,266 reads/million), HHV-1 (484 reads/million) was predominant in the sputum. Then, mNGS re-examinations of samples including sputum, blood, NP, lung lavage, and stomach fluid were performed immediately on Day 18. The results showed the amount of HHV-1 in sputum increased to 81,098 reads per million (RPM). HHV-1 was also detected in blood (44 RPM), NP (89,833 RPM), lung lavage (8 RPM) and stomach fluid (46 RPM), suggesting a latent reactivation of HHV-1 (Figure 3). Guided by these sequencing results, an anti HHV-1 agent, acyclovir (0.5 g, intravenous every 8 h), was initiated. After 14 days of anti-HHV-1 therapy, the number of HHV-1 reads decreased and reached to single digit level of RPM. The patient's clinical condition improved, with normal body temperature, heart rate (62 beats per minute), breathing rate (15 breaths per minute), oxygen saturation of 97–100%, and white blood cell count (8.97×10^9 cells/L). Chest X-ray showed the lesions in the lower right lung were no longer visible.

In subsequent days, the patient's clinical symptoms continued to improve, SARS-CoV-2 tests in sputum and NP maintained negative, and mNGS revealed no HHV-1 reads in sputum and blood. After 49 days on ECMO (February 9th-March 28th) and 67 days on the ventilator (February 6th-April 13th), the patient recovered and was finally discharged.

**DISCUSSION AND CONCLUSIONS**

To the best of our knowledge, this is the first report describing re-activation of latent HHV-1 in a critically ill COVID-19 patient with prolonged ECMO support. HHV-1 is a double stranded DNA virus of genus Simplexvirus, family Herpesviridae. HHV-1 commonly resides in sensory ganglia in latency. A variety of stimuli such as stress, fever and immune suppression can trigger lytic replication and result in production of infectious virus (10). In an immune competent patient, HHV-1 infection is mild and self-limiting. However, HHV-1 infection can be severe and prolonged in immunocompromised individuals without treatment, leading to significant morbidity and mortality (11). In this report, the lymphocyte count of the patient decreased significantly when admitted to the hospital for COVID-19 and during hospitalization. Lymphopenia is common in severe COVID-19 patients (12). ECMO therapy is also associated with a decrease of lymphocyte count and functionality (13). Interestingly, CD8+ T cells play an essential role in preventing HHV-1 reactivation (14). The lower levels of lymphocytes in the reported patient might have permitted or promoted the reactivation of HHV-1 virus (15). Anti-HHV-1 therapy using acyclovir decreased HHV-1 load and alleviated the patient's clinical symptoms, indicating the significance of HHV-1 infection in the COVID-19 patient. We don't have direct evidence of HHV-1 pneumonia, but the clinical scenario (mNGS detection and the effect of anti HHV-1 treatment) is highly suggestive of causation.

Our report calls for awareness of latent virus reactivation in severe COVID-19 patients, particularly when infectious agents...
are unknown. Identification of latent virus activation becomes a challenging task for the routine diagnostic tests if the causative agents are unknown. Our report utilized mNGS technology, which successfully detected HHV-1 DNA in multiple body sites, and was valuable in monitoring the dynamics of viral loads over treatment course.

mNGS is a new pan-pathogen detection technology, which can theoretically detect all known pathogens including bacteria, viruses, fungi, and parasites in one run, with unbiased results. Compared to the conventional diagnostic methods, mNGS has a higher sensitivity and specificity and costs less time. In this case report, mNGS successfully detected HHV-1 in different types of samples, including sputum, blood, NP, lung lavage, and stomach fluid within 2 days, indicating significant advantages in the diagnosis of pathogens, which contributes to a timely treatment to the patient.

In conclusion, we present a case of COVID-19 with HHV-1, followed by HHV-1 reactivation that exacerbated the condition of COVID-19. mNGS was used for the rapid clinical diagnosis of the pathogen, demonstrating the potential value of metagenomics for evidence-based treatment. This case report suggests that potential reactivation of latent viruses should be considered in critically ill COVID-19 patients.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT
The study was approved by the Ethics Review Committee of the First Affiliated Hospital of Xi’an Jiaotong University. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS
LS, QL, YZ, and TC designed research. LS, HX, FD, GZ, JL, QH, WF, FY, SL, ZL, HL, YW, JY, and TC analyzed data. LS, HX, MM, CD, NL, HR, YC, JLIu, and TC wrote the paper. All authors have read and approved the manuscript.

FUNDING
This study was funded by the Key R&D plan of Shaanxi Province, China (number 2020ZDXM-SF-004). The funding body had no role in study design; collection, analysis, and interpretation of data; writing of the report; or the decision to submit the paper for publication.

ACKNOWLEDGMENTS
We thank all health care workers and show the greatest appreciation to all those involved in the treatment of disease. We also thank Dr. Yanjiao Zhou for language editing of the manuscript.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.715519/full#supplementary-material.

REFERENCES
1. Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med. (2020) 20:124-7. doi: 10.7861/clinmed.2019-coron
2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. (2020) 323:1061-9. doi: 10.1001/jama.2020.1585
3. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest. (2020) 130:2620-9. doi: 10.1172/JCI137244
4. Kim D, Quin J, Pinsky B, Shah NH, Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. (2020) 323:2085-6. doi: 10.1001/jama.2020.6266
5. Ayoub HH, Chemaitelly H, Abu-Raddad LJ. Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions. BMC Med. (2019) 17:57. doi: 10.1186/s12916-019-1285-x
6. Sukik L, Alyafei M, Harfouche M, Abu-Raddad LJ. Herpes simplex virus type 1 epidemiology in Latin America and the Caribbean: Systematic review and meta-analyses. PLoS ONE. (2019) 14:e0215487. doi: 10.1371/journal.pone.0215487
7. Khadr L, Harfouche M, Omori R, Schwarzer G, Chemaitelly H, Abu-Raddad LJ. The epidemiology of herpes simplex virus type 1 in Asia: systematic review, meta-analyses, and meta-regressions. Clin Infect Dis. (2019) 68:757-72. doi: 10.1093/cid/ciy562
8. Chaabane S, Harfouche M, Chemaitelly H, Schwarzer G, Abu-Raddad LJ. Herpes simplex virus type 1 epidemiology in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions. Sci Rep. (2019) 9:1136. doi: 10.1038/s41598-018-37833-8
9. Cantan B, Luyt CE, Martin-Löeches I. Influenza infections and emergent viral infections in intensive care unit. Semin Respir Crit Care Med. (2019) 40:488-97. doi: 10.1055/s-0039-1693497
10. Suzich JR, Cliffe AR. Strength in diversity: Understanding the pathways to herpes simplex virus reactivation. Virology. (2018) 522:81-91. doi: 10.1016/j.virol.2018.07.011
11. Herget GW, Riede UN, Schmitt-Graff A, Lubbert M, Neumann-Haefelin D, Kohler G. Generalized herpes simplex virus infection in an immunocompromised patient—report of a case and review of the literature. Pathol Res Pract. (2005) 201:123-9. doi: 10.1016/j.prrp.2004.12.003
12. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China medical treatment expert group for, clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708–20. doi: 10.1056/NEJMc2002302
13. Bizzarro MJ, Conrad SA, Kaufman DA, Rycus P. Extracorporeal Life Support Organization Task Force on Infections. Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med. (2011) 12:277-81. doi: 10.1097/PCC.0b013e318e28894

Frontiers in Medicine | www.frontiersin.org
October 2021 | Volume 8 | Article 715519 | 4

Shi et al. SARS-CoV-2 and HHV-1 Reactivation
14. Orr MT, Mathis MA, Lagunoff M, Sacks JA, Wilson CB. CD8 T cell control of HSV reactivation from latency is abrogated by viral inhibition of MHC class I. *Cell Host Microbe.* (2007) 2:172-80. doi: 10.1016/j.chom.2007.06.013

15. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. *J Infect Dis.* (2020) 221:1762-9. doi: 10.1093/infdis/jiaa150

**Conflict of Interest:** HX is employed by Hugobiotech Beijing Co., Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Shi, Xia, Moore, Deng, Li, Ren, Chen, Liu, Du, Zheng, Li, Han, Fan, Ye, Lin, Liu, Wang, Yang, Liu, Zhao and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.